Celon Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was zł3.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł2.99.
During the past 3 years, the average EBIT per Share Growth Rate was 14.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -25.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Celon Pharma's EBIT per Share or its related term are showing as below:
WAR:CLN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -59.4 Med: -33 Max: 14.4
Current: 14.4
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Celon Pharma was 14.40% per year. The lowest was -59.40% per year. And the median was -33.00% per year.
WAR:CLN's 3-Year EBIT Growth Rate is ranked better than 60.62% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs WAR:CLN: 14.40
Celon Pharma's EBIT for the
three
months ended in Mar. 2026 was zł160.8 Mil.
Celon Pharma (WAR:CLN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Celon Pharma EBIT per Share Related Terms
Celon Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Celon Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (WAR:CLN) has a EBIT per Share of zł2.99 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #319 out of 810 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is Celon Pharma's EBIT per Share too high?
Celon Pharma's current EBIT per Share is zł2.99. Based on the distribution chart, Celon Pharma ranks #319 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #319 out of 810 companies for EBIT per Share. This puts Celon Pharma in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current EBIT per Share is zł2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.36, compared to a current price of zł19.70 — trading 15.7% below its estimated fair value. The current EBIT per Share is zł2.99. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current EBIT per Share is zł2.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.70 is trading 15.7% below its estimated GF Value™ of zł23.36.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
EBIT per Share: zł2.99
GF Value™: zł23.36 vs. price of zł19.70 (15.7% below fair value)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score
Get the complete analysis for WAR:CLN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
